tbuckley/cabot-search huggingface dataset:
Methotrexate and Cyclosporin Improve Skin Biomarkers in Paediatric Atopic Dermatitis: Results from the TREatment of Severe Atopic Eczema Trial
Authors: Helen Alexander, Saerrah Murryam, Sanja Kezic, Ehsan Motazedi, David Prieto-Merino, Alan D Irvine, Carsten Flohr
Journal: British Journal of Dermatology (2025)

Methotrexate (MTX) and cyclosporin (CyA) are the main conventional systemic treatments for severe atopic dermatitis (AD) globally. Despite the emergence of advanced targeted therapies for AD, the complex interaction of cutaneous immune biomarkers and their modulation during systemic therapy remains poorly understood. Our study utilises the skin cytokine profiles from the Treatment of severe Atopic Eczema in children Trial (TREAT) to explore skin immune biomarkers in paediatric patients randomised to either CyA or MTX treatment. Our findings suggest that while both MTX and CyA modulate the cutaneous immune response, MTX has a more pronounced effect on certain immunological and skin barrier biomarkers compared to CyA, even after treatment cessation.
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)
Authors: Sandeep Brar, Rahul Goli, Joshua P Barrios, Michael J Blaha, Sina Kianoush, Mark J Pletcher, Sarah O Nomura, Michael Y Tsai, Rong Duan, Matthew J Budoff, Moyses Szklo, Geoffrey H Tison
Journal: JACC Heart Failure (2025)
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Authors: Chunxiang Jin, Rongrong Chen, Shan Fu, Mingming Zhang, Yuanyin Teng, Tingting Yang, Fengmei Song, Jingjing Feng, Ruimin Hong, Jiazhen Cui, Simao Huang, Huijun Xu, Yanlei Zhang, Guoqing Wei, Zhen Cai, Yok-Lam Kwong, Thomas Sau Yan Chan, Alex H Chang, He Huang, Yongxian Hu
Journal: Journal for ImmunoTherapy of Cancer (2025)

B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell immunotherapy has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). This study presents the updated long-term outcomes from our center. Between July 30, 2018, and September 27, 2023, 141 patients with R/RMM who received BCMA CAR-T therapy were enrolled. Patients underwent conditioning chemotherapy with cyclophosphamide and fludarabine, followed by BCMA CAR-T cell infusion at a median dose of 2.36×106 cells/kg. The study evaluated overall response rates, long-term efficacy, safety profiles, and their associations with clinical and disease characteristics. At a median follow-up of 20.2 months, the safety profile of the therapy was manageable. Grade 3/4 cytokine release syndrome occurred in 36.2% of patients, with no cases of severe neurotoxicity reported. 1-month post-infusion, grade ≥3 anemia persisted in 39.6% of patients, while neutropenia (43.3%) and thrombocytopenia (52.2%) were observed. The objective response rate (ORR) among evaluable patients was 94.8%, with 50.7% achieving a complete response (CR). The 4-year progression-free survival and overall survival rates were 37.4% (95% CI, 29.1% to 48.1%) and 63.2% (95% CI, 54.8% to 72.8%), respectively, with survival curves showing gradual flattening over time. Patients with a history of autologous stem cell transplantation (ASCT) and those with extramedullary disease demonstrated significantly inferior efficacy and survival outcomes. Peak CAR-T cell expansion was positively correlated with ORR (p<0.001) and CR (p<0.001). Notably, patients with prior ASCT exhibited significantly lower CAR-T cell expansion compared with those without prior ASCT (p<0.001). Immunophenotypic analysis of infused CAR-T cells demonstrated impaired fitness in patients who received ASCT in the past year. BCMA CAR-T therapy in patients with R/RMM results in significant and sustained responses, with a manageable safety profile on a large scale. Prior ASCT and extramedullary disease represent adverse prognostic factors. Patients with a history of ASCT demonstrate limited peak CAR-T cell expansion.
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Authors: Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas, Christina J Falcon, Princess Margaret Lung Group, Matthew A Gubens, Scott Huntsman, Khaleeq Khan, Min Li, Christine M Lovly, Devalben Patel, Luna Jia Zhan, Geoffrey Liu, Melinda C Aldrich, Adam Schoenfeld, Elad Ziv
Journal: Journal for ImmunoTherapy of Cancer (2025)

Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors, but they also commonly cause immune-related adverse events (irAEs). The predictive features of clinically severe irAEs leading to cessation of ICIs have yet to be established. Given the similarities between irAEs and autoimmune diseases, we sought to investigate the association of a germline polygenic risk score for autoimmune disease and discontinuation of ICIs due to irAEs. The Genetics of immune-related adverse events and Response to Immunotherapy (GeRI) cohort comprises 1302 patients with non-small cell lung cancer (NSCLC) who received ICI therapy between 2009 and 2022 at four academic medical centers. We used a published polygenic risk score for autoimmune diseases (PRSAD) in the general population and validated it in the All of Us. We then assessed the association between PRSAD and cessation of ICI therapy due to irAEs in the GeRI cohort, using cause-specific and Fine-Gray subdistribution hazard models. To further understand the differential effects of type of therapy on the association between PRSAD and cessation of ICI due to irAEs, we conducted a stratified analysis by type of ICI therapy. Using a competing risk model, we found an association between PRSAD and ICI cessation due to irAEs (HR per SD=1.24, p=0.004). This association was particularly strong in patients who had ICI cessation due to irAEs within 3 months of therapy initiation (HR per SD=1.40, p=0.005). Individuals in the top quintile of PRSAD had 4.8% ICI discontinuation for irAEs by 3 months, compared with 2% discontinuation by 3 months among patients in the bottom quintile (log-rank p=0.03). In addition, among patients who received combination programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors and cytotoxic T-lymphocyte associated protein 4 (CTLA4) inhibitors, ICI discontinuation for irAEs by 3 months occurred in 4 of the 13 patients (30.8%) with high PRSAD genetic risk (top quintile) versus 3 of 21 patients (14.3%) with low PRSAD genetic risk (bottom quintile). We demonstrate an association between a polygenic risk score for autoimmune disease and early ICI discontinuation for irAEs. Our results suggest that germline genetics may be used as an adjunctive tool for risk stratification around ICI clinical decision-making in solid tumor oncology.
CLO25-099: Lenvatinib With Pembrolizumab in Advanced Biliary Tract Cancer
Authors: Kabir Grewal, Shubham Pant, Ian Hu, Madhulika Eluri, Amy An, Victoria Higbie, Ryan Huey, Ahmed Kasab, Milind Javle, Sunyoung Lee
Journal: Journal of the National Comprehensive Cancer Network (2025)
EPR25-121: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients: Testing and Referral Guidelines
Authors: Teodora Kuzmanovic, Maedeh Zoakei Nikoo, Sindhusha Veereballi, Ahmad Safdar, Sakthi S. Prakash, Emmett Samsa, David Bosler, Halle C. F. Moore, Jame Abraham, Jessica Geiger, Aaron T. Gerds, Anjali S. Advani, Sudipto Mukherjee, John C. Molina, Sophia Balderman, Moaath Mustafa Ali, Jaroslaw P. Maciejewski, Akriti Jain, Hetty Carraway, Bhumika Patel, Rohit Moudgil, Abhay Singh
Journal: Journal of the National Comprehensive Cancer Network (2025)
Using natural experiments to evaluate population health and health system interventions: new framework for producers and users of evidence
Authors: Peter Craig, Mhairi Campbell, Manuela Deidda, Ruth Dundas, Judith Green, Srinivasa Vittal Katikireddi, Jim Lewsey, David Ogilvie, Frank de Vocht, Martin White
Journal: BMJ (2025)

Natural experiments are widely used to evaluate the impacts on health of changes in policies, infrastructure, and services. The UK Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) have published a new framework for conducting and using evidence from natural experimental evaluations. The framework defines key concepts and describes recent advances in designing and planning evaluations of natural experiments, including the relevance of a systems perspective, mixed methods, and stakeholder involvement. It provides an overview of the strengths, weaknesses, applicability, and limitations of the range of methods now available, and makes good practice recommendations for researchers, funders, publishers, and users of evidence.
CRE25-045: Delayed Detection of Liver Metastasis in Granulosa Cell Tumor Due to Healthcare Disparities: A Case Report and Literature Review
Authors: Xiaowei Malone, Otto Walter, Kenneth Snell
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CRE25-045: Delayed Detection of Liver Metastasis in Granulosa Cell Tumor Due to Healthcare Disparities: A Case Report and Literature Review" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient
Authors: Sahithee Alekhya Batchu, Yue Ma, Sue Yom, Chase Heaton, Alain Algazi
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CRE25-043: Treatment of HER2-Positive Breast Cancer With Leptomeningeal Metastases With Intrathecal Trastuzumab
Authors: Vasu Munjapara, John Rice, Lindsay Robell, Kelsey Peters, Denise Leung, Yoshie Umemura, Aaron Mammoser, Aki Morikawa, Larry Junck
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-194: Trends in Depression and Its Unequal Burden in Cancer Survivors With Socioeconomic Disparities.
Authors: Amara Sofia, Ahmad Alhomaid, Nency K. Ganatra, Aditya Sanjeevi, Rupak Desai, Akhil Jain, Rishika Trivedi
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-197: The Correlation of Resilience, Family Hardiness and Quality of Life of Patients With Soft Tissue Sarcoma and Family Caregivers Based on a Binary Perspective
Authors: Yikai Kong, Lei Xu, Ruiqi Shu, Yuanyuan Li, Maoting Tian, Jiayang Zhang, Yiwen Chen
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-197: The Correlation of Resilience, Family Hardiness and Quality of Life of Patients With Soft Tissue Sarcoma and Family Caregivers Based on a Binary Perspective" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis
Authors: Zin Myint, Kris Varothai, Megan Foley, Donglin Yan
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using a human challenge model (CHIPS): a randomised, double-blind, placebo-controlled trial
Authors: Thel K Hla, Joshua Osowicki, Julie A Marsh, Sam Salman, Madhu Page-Sharp, Okhee Yoo, Kristy Azzopardi, Michael Morici, Kevin T Batty, Renae K Barr, Stephanie L Enkel, Joseph Kado, Lara Hatchuel, Alma Fulurija, James S McCarthy, Thomas L Snelling, Andrew C Steer, Jonathan Carapetis, Laurens Manning
Journal: The Lancet Microbe (2025)

The in-vivo plasma concentration of penicillin needed to prevent Streptococcus pyogenes pharyngitis, recurrent acute rheumatic fever, and progressive rheumatic heart disease is not known. We used a human challenge model to assess the minimum penicillin concentration required to prevent streptococcal pharyngitis. In CHIPS, a randomised, double-blind, placebo-controlled, human challenge trial, healthy adult volunteers were randomly assigned by a computer-generated random sequence to target steady-state penicillin plasma concentrations (placebo, 3, 6, 9, 12, or 20 ng/mL). The study was a single-centre trial held in Perth, WA, Australia. Participants had to be healthy adults, aged 18-40 years, at low risk of complicated S pyogenes disease, and without high type-specific IgG antibodies against the emm75 S pyogenes challenge strain. Participants and staff involved in clinical care remained masked to treatment allocation for the duration of the study. Individualised 5-day continuous intravenous infusions of penicillin were commenced 12 h before direct pharyngeal application of the emm75 challenge strain. The primary endpoint was clinical pharyngitis. This trial is registered on the Australian New Zealand Clinical Trials Registry, ACTRN12621000751875, and is completed. Between Aug 23, 2022, and July 31, 2023, 60 participants were randomly assigned (35 [58%] were female and 25 [42%] were male), with 57 included in the analysis. The clinical pharyngitis endpoint was met in eight (57%) of 14 in the placebo group, four (44%) of nine in the 3 ng/mL target steady-state penicillin plasma concentration group, four (44%) of nine in the 6 ng/mL group, none of eight in the 9 ng/mL group, none of eight in the 12 ng/mL group, and none of nine in the 20 ng/mL group. No severe or serious adverse events occurred. Using Bayesian concentration-response modelling, the minimum steady-state plasma concentration of penicillin for which 90% of participants would avoid clinical pharyngitis was 8·1 ng/mL (95% credible interval 6·1-10·9). When steady-state penicillin concentrations are greater than 9 ng/mL, few people will develop experimental emm75 S pyogenes pharyngitis. These data will inform efforts to improve long-acting penicillin preparations and dosage regimens to prevent recurrent rheumatic fever and rheumatic heart disease. The National Health and Medical Research Council of Australia.
CRE25-036: Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC): A Mayo Clinic Multidisciplinary Approach to Treatment
Authors: Dhauna Karam Prasad, Kimberly S. Corbin, Tina Hieken, Samir Mardini, Malvika Solanki, Svetomir Markovic, Mathew Block, Ciara O’Sullivan
Journal: Journal of the National Comprehensive Cancer Network (2025)
CRE25-037: Paraneoplastic Syndrome in Undifferentiated Pleomorphic Sarcoma Demonstrates Acquired Antithrombin III Deficiency as Risk Factor for Cancer-Related Morbidity
Authors: Adrese Michael Kandahari, Carmelo Puccio
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CRE25-037: Paraneoplastic Syndrome in Undifferentiated Pleomorphic Sarcoma Demonstrates Acquired Antithrombin III Deficiency as Risk Factor for Cancer-Related Morbidity" published on 28 Mar 2025 by National Comprehensive Cancer Network.
PCO25-212: Examining Molecular Features of Rare Brain Metastases Patient-Derived Xenograft Models
Authors: Noreen F. Khan, Derek Nancarrow, Peter Ulintz, Tusharika Rastogi, Habib Serhan, Xu Cheng, Liwei Bao, Aaron Udager, Matthew Soellner, Edwin Nieblas-Bedolla, Jason Heth, Nathan Merrill, Sofia D. Merajver, Aki Morikawa
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-193: Characterizing Influences to Multidisciplinary Team Care in Resectable Non-Small Cell Lung Cancer: A Qualitative Study
Authors: Daniel Simmons, Emily Mulvihill, Nicole Kashine, Stephanie Tomazin, David Cornwall, Silas Hartley, Stephanie Loomer, Nicholas Theilen, Tiernan Mulrooney, Melody Hughes, Debora Bruno
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era
Authors: Xiao Wang, Jessica B. Long, John Rothen, Pamela R. Soulos, Timothy J. Robinson, Carolyn J. Presley, Sarah B. Goldberg, Ronac Mamtani, Shi-Yi Wang, Natalia Kunst, Shuangge Ma, Sida Huang, Cary P. Gross, Michaela A. Dinan
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality
Authors: Harrison Nguyen, Christine N. Bailey, Brian Martin, Sonia K. Morgan-Linnell, Valentina I. Petkov, Michael Tassavor
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-061: 7-Gene Biosignature Reclassified Women With DCIS Meeting NCCN Guideline (RTOG 9804-Like) Low-Risk Criteria as Molecular High Risk
Authors: Chirag Shah, Frank A. Vicini, Eileen P. Connolly, Rachel A. Rabinovitch, Brian Czerniecki, Gregory Bruce Mann, Pat W. Whitworth, Karuna Mittal, Steve Shivers, Troy Bremer
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-061: 7-Gene Biosignature Reclassified Women With DCIS Meeting NCCN Guideline (RTOG 9804-Like) Low-Risk Criteria as Molecular High Risk" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BPI25-021: Validating Navya Earthshot: An AI Driven Point of Care Solution for Guideline Adherent Treatment Planning in a Decentralized Cancer Care Model
Authors: Umesh M. Mahantshetty, Shilpa Kandipalli, Guru Raghavendra Naik, Motepalli Panduranga Kumari, Padmanaban Srinivasan, Raviteja Miriyala, Shveta Sharma, Ramya Balasubramanyam, Nagashayana Gampalahalli, Arpitha Chinnu Sabu, Rhea Mehta, Dolorosa Fernandes
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-021: Validating Navya Earthshot: An AI Driven Point of Care Solution for Guideline Adherent Treatment Planning in a Decentralized Cancer Care Model" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-062: Prevalence of Cannabis Use Disorder Among Hospitalized Elderly Cancer Survivors: Nationwide Trends and Disparities (2016–2020)
Authors: Sai Gautham Kanagala, Neha Singh, Laxman Yashwant Byreddi, Thanmai Reddy Thugu, Muskan Jain, Neeharika John Madhavaram, Diksha Sanjana Pasnoor, Sonali Dash, Ahmad Alhomaid, Akhil Jain, Rupak Desai
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-062: Prevalence of Cannabis Use Disorder Among Hospitalized Elderly Cancer Survivors: Nationwide Trends and Disparities (2016–2020)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-059: Exploring Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Squamous Cell Carcinoma (LSCC) in North America
Authors: Justin W. Shi, Ahmad Karkash, Weston He, Mya Tran, Misty Dawn Shields, Julian A. Marin-Acevedo
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-015: Implementing a No-Cost Strategy to Minimize Blood Product Waste in a High-Volume Hematology/Oncology Intermediate Care Unit
Authors: Bindu Kuriacose, Annie Abraham, Neicole James
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-015: Implementing a No-Cost Strategy to Minimize Blood Product Waste in a High-Volume Hematology/Oncology Intermediate Care Unit" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CGE25-108: Uncovering APOBEC Mutational Signatures in Cancer: The Power of Whole Genome Sequencing for Comprehensive Genomic Profiling
Authors: Erin Connolly-Strong, Ryul Kim, Brain Beak-Lok Oh, Chunyang Bao, Jung Ah Kim, Eun Kyong Lee, Jeong-Hoon Lee, Amy Ackershoek, Sangmoon Lee, Minsuk Kwon
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CGE25-108: Uncovering APOBEC Mutational Signatures in Cancer: The Power of Whole Genome Sequencing for Comprehensive Genomic Profiling" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CGE25-105: Microrna Expression Profiles in Non-Small Cell Lung Cancer Related Pleural Effusion and Its Prognostic Significance in Treatment Response and Survival Outcome
Authors: Niyas Amir, Anoop TM, Preethi Sara George, Lakshmi S
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CGE25-105: Microrna Expression Profiles in Non-Small Cell Lung Cancer Related Pleural Effusion and Its Prognostic Significance in Treatment Response and Survival Outcome" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines
Authors: Emily S. Ruiz, Karina Brito, Emily E. Karn, R'ay Fodor, Allison T. Vidimos, Shauna R. Campbell, David M. Wang, Jennifer J. Siegel, Brian J. Martin, Jason H. Rogers, Matthew S. Goldberg, Kelsey E. Hirotsu, Nima Gharavi, Shlomo A. Koyfman
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-071: The Impact of ChemoMouthpiece Device on Analgesic Use for Oral Pain in a Randomized, Prospective, Multi-Center Trial for Patients Undergoing Stomatoxic Chemotherapy
Authors: Vikas Dembla, Richard Zuniga
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-071: The Impact of ChemoMouthpiece Device on Analgesic Use for Oral Pain in a Randomized, Prospective, Multi-Center Trial for Patients Undergoing Stomatoxic Chemotherapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-248: Hypofractionated Postmastectomy Irradiation During COVID-19: Safety, Efficacy, and Patient-Centered Care – A Single Institution Experience
Authors: Salwa Fathy, Seham Abdelkhalek, Nasser Al-Dhaibani, Maha Alidrisi, Duaa Alhawi, Mazen Al-Gaoud
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-248: Hypofractionated Postmastectomy Irradiation During COVID-19: Safety, Efficacy, and Patient-Centered Care – A Single Institution Experience" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-089: The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Predicting Clinical and Survival Outcomes and Treatment Response for Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Authors: Rishabh Arun Vashisht, Nency Kashyap Ganatra, Diksha Sanjana Pasnoor, Mohit Mirchandani, Beenish Najam, Akhil Jain, Rupak Desai
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-089: The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Predicting Clinical and Survival Outcomes and Treatment Response for Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR-T) Therapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-056: Does Adjuvant Therapy Improve Survival Following Upfront Esophagectomy? Real World Evidence - Based on National Cancer Database Analysis
Authors: Srineil Vuthaluru, Collin Dougherty, Quan P. Ly
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-056: Does Adjuvant Therapy Improve Survival Following Upfront Esophagectomy? Real World Evidence - Based on National Cancer Database Analysis" published on 28 Mar 2025 by National Comprehensive Cancer Network.